NO309529B1 - Aprotininanaloger - Google Patents

Aprotininanaloger Download PDF

Info

Publication number: NO309529B1
Authority: NO; Norway
Prior art keywords: aprotinin; glu; amino acid; ser; acid residue
Prior art date: 1990-10-01

Application number

NO931220A

Other languages

English (en)

Norwegian (no)

Other versions

NO931220L (no

NO931220D0 (no

Inventor

Soeren Erik Bjoern

Kjeld Norris

Viggo Diness

Leif Noerskov-Lauritsen

Niels Dyhr Christensen

Claus Bregengaard

Original Assignee

Novo Nordisk As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-10-01

Filing date

1993-03-31

Publication date

2001-02-12

1990-10-01 Priority claimed from DK236190A external-priority patent/DK236190D0/da

1991-06-12 Priority claimed from DK111891A external-priority patent/DK111891D0/da

1993-03-31 Application filed by Novo Nordisk As filed Critical Novo Nordisk As

1993-03-31 Publication of NO931220D0 publication Critical patent/NO931220D0/no

1993-04-01 Publication of NO931220L publication Critical patent/NO931220L/no

2001-02-12 Publication of NO309529B1 publication Critical patent/NO309529B1/no

Links

ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 title claims abstract description 193
229960004405 aprotinin Drugs 0.000 title claims description 133
108010039627 Aprotinin Proteins 0.000 title claims description 99
125000000539 amino acid group Chemical group 0.000 claims abstract description 82
230000002829 reductive effect Effects 0.000 claims abstract description 31
108091005804 Peptidases Proteins 0.000 claims abstract description 15
206010029155 Nephropathy toxic Diseases 0.000 claims abstract description 14
239000004365 Protease Substances 0.000 claims abstract description 14
231100000417 nephrotoxicity Toxicity 0.000 claims abstract description 14
230000007694 nephrotoxicity Effects 0.000 claims abstract description 14
230000007935 neutral effect Effects 0.000 claims abstract description 12
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims abstract 3
238000000034 method Methods 0.000 claims description 48
210000004027 cell Anatomy 0.000 claims description 32
238000004519 manufacturing process Methods 0.000 claims description 31
108091028043 Nucleic acid sequence Proteins 0.000 claims description 22
239000013598 vector Substances 0.000 claims description 13
108020004414 DNA Proteins 0.000 claims description 11
229910052739 hydrogen Inorganic materials 0.000 claims description 11
239000001257 hydrogen Substances 0.000 claims description 11
YBTCBQBIJKGSJP-BQBZGAKWSA-N Glu-Pro Chemical compound OC(=O)CC[C@H](N)C(=O)N1CCC[C@H]1C(O)=O YBTCBQBIJKGSJP-BQBZGAKWSA-N 0.000 claims description 6
229940079593 drug Drugs 0.000 claims description 6
239000003814 drug Substances 0.000 claims description 6
239000013604 expression vector Substances 0.000 claims description 6
108090000765 processed proteins & peptides Proteins 0.000 claims description 6
241000024188 Andala Species 0.000 claims description 4
238000003259 recombinant expression Methods 0.000 claims description 4
239000007864 aqueous solution Substances 0.000 claims description 3
230000015572 biosynthetic process Effects 0.000 claims description 3
210000004899 c-terminal region Anatomy 0.000 claims description 3
WPWUFUBLGADILS-WDSKDSINSA-N Ala-Pro Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(O)=O WPWUFUBLGADILS-WDSKDSINSA-N 0.000 claims description 2
LQJAALCCPOTJGB-YUMQZZPRSA-N Arg-Pro Chemical compound NC(N)=NCCC[C@H](N)C(=O)N1CCC[C@H]1C(O)=O LQJAALCCPOTJGB-YUMQZZPRSA-N 0.000 claims description 2
UKGGPJNBONZZCM-WDSKDSINSA-N Asp-Pro Chemical compound OC(=O)C[C@H](N)C(=O)N1CCC[C@H]1C(O)=O UKGGPJNBONZZCM-WDSKDSINSA-N 0.000 claims description 2
108010016626 Dipeptides Proteins 0.000 claims description 2
LNCFUHAPNTYMJB-IUCAKERBSA-N His-Pro Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(O)=O)C1=CN=CN1 LNCFUHAPNTYMJB-IUCAKERBSA-N 0.000 claims description 2
BBIXOODYWPFNDT-CIUDSAMLSA-N Ile-Pro Chemical compound CC[C@H](C)[C@H](N)C(=O)N1CCC[C@H]1C(O)=O BBIXOODYWPFNDT-CIUDSAMLSA-N 0.000 claims description 2
125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 claims description 2
VTJUNIYRYIAIHF-IUCAKERBSA-N Leu-Pro Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(O)=O VTJUNIYRYIAIHF-IUCAKERBSA-N 0.000 claims description 2
KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 claims description 2
WBAXJMCUFIXCNI-WDSKDSINSA-N Ser-Pro Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(O)=O WBAXJMCUFIXCNI-WDSKDSINSA-N 0.000 claims description 2
QOLYAJSZHIJCTO-VQVTYTSYSA-N Thr-Pro Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(O)=O QOLYAJSZHIJCTO-VQVTYTSYSA-N 0.000 claims description 2
108010087924 alanylproline Proteins 0.000 claims description 2
108010060035 arginylproline Proteins 0.000 claims description 2
108010093581 aspartyl-proline Proteins 0.000 claims description 2
KZNQNBZMBZJQJO-YFKPBYRVSA-N glyclproline Chemical compound NCC(=O)N1CCC[C@H]1C(O)=O KZNQNBZMBZJQJO-YFKPBYRVSA-N 0.000 claims description 2
108010077515 glycylproline Proteins 0.000 claims description 2
108010085325 histidylproline Proteins 0.000 claims description 2
108010057821 leucylproline Proteins 0.000 claims description 2
230000008569 process Effects 0.000 claims description 2
108010026333 seryl-proline Proteins 0.000 claims description 2
125000004435 hydrogen atom Chemical class [H]* 0.000 claims 10
102000053602 DNA Human genes 0.000 claims 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 74
235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 72
239000013612 plasmid Substances 0.000 description 55
239000012634 fragment Substances 0.000 description 41
238000002360 preparation method Methods 0.000 description 27
210000003734 kidney Anatomy 0.000 description 24
239000000463 material Substances 0.000 description 18
241000700159 Rattus Species 0.000 description 16
108700005078 Synthetic Genes Proteins 0.000 description 16
239000006228 supernatant Substances 0.000 description 16
108091034117 Oligonucleotide Proteins 0.000 description 14
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 14
108090000623 proteins and genes Proteins 0.000 description 14
231100000041 toxicology testing Toxicity 0.000 description 14
239000007222 ypd medium Substances 0.000 description 14
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 13
238000004458 analytical method Methods 0.000 description 13
239000013613 expression plasmid Substances 0.000 description 13
210000002700 urine Anatomy 0.000 description 13
102000035195 Peptidases Human genes 0.000 description 12
238000009825 accumulation Methods 0.000 description 11
230000002401 inhibitory effect Effects 0.000 description 11
235000019419 proteases Nutrition 0.000 description 11
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
238000010276 construction Methods 0.000 description 10
238000006467 substitution reaction Methods 0.000 description 9
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 8
150000001413 amino acids Chemical class 0.000 description 8
239000000600 sorbitol Substances 0.000 description 8
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 7
239000007924 injection Substances 0.000 description 7
238000002347 injection Methods 0.000 description 7
210000005084 renal tissue Anatomy 0.000 description 7
108060005987 Kallikrein Proteins 0.000 description 6
102000001399 Kallikrein Human genes 0.000 description 6
108010076504 Protein Sorting Signals Proteins 0.000 description 6
125000003275 alpha amino acid group Chemical group 0.000 description 6
230000000875 corresponding effect Effects 0.000 description 6
238000004925 denaturation Methods 0.000 description 6
230000036425 denaturation Effects 0.000 description 6
230000000694 effects Effects 0.000 description 6
239000012528 membrane Substances 0.000 description 6
239000000203 mixture Substances 0.000 description 6
230000010076 replication Effects 0.000 description 6
230000004044 response Effects 0.000 description 6
239000000243 solution Substances 0.000 description 6
241000588724 Escherichia coli Species 0.000 description 5
238000003556 assay Methods 0.000 description 5
230000037396 body weight Effects 0.000 description 5
230000008859 change Effects 0.000 description 5
230000002538 fungal effect Effects 0.000 description 5
239000003112 inhibitor Substances 0.000 description 5
210000004185 liver Anatomy 0.000 description 5
210000004962 mammalian cell Anatomy 0.000 description 5
239000002609 medium Substances 0.000 description 5
101000713596 Homo sapiens T-box transcription factor TBX19 Proteins 0.000 description 4
102100036773 T-box transcription factor TBX19 Human genes 0.000 description 4
101150033985 TPI gene Proteins 0.000 description 4
230000002052 anaphylactic effect Effects 0.000 description 4
238000005119 centrifugation Methods 0.000 description 4
230000029142 excretion Effects 0.000 description 4
210000000110 microvilli Anatomy 0.000 description 4
102000004169 proteins and genes Human genes 0.000 description 4
238000001356 surgical procedure Methods 0.000 description 4
239000000725 suspension Substances 0.000 description 4
238000001712 DNA sequencing Methods 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
241000700157 Rattus norvegicus Species 0.000 description 3
241000235347 Schizosaccharomyces pombe Species 0.000 description 3
229960000723 ampicillin Drugs 0.000 description 3
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
230000000740 bleeding effect Effects 0.000 description 3
239000008280 blood Substances 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
230000002612 cardiopulmonary effect Effects 0.000 description 3
210000001715 carotid artery Anatomy 0.000 description 3
230000015556 catabolic process Effects 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
238000001990 intravenous administration Methods 0.000 description 3
238000004255 ion exchange chromatography Methods 0.000 description 3
102000004196 processed proteins & peptides Human genes 0.000 description 3
230000017854 proteolysis Effects 0.000 description 3
210000005234 proximal tubule cell Anatomy 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
238000012360 testing method Methods 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
230000002110 toxicologic effect Effects 0.000 description 3
231100000027 toxicology Toxicity 0.000 description 3
101150080369 tpiA gene Proteins 0.000 description 3
230000009466 transformation Effects 0.000 description 3
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
229920001817 Agar Polymers 0.000 description 2
102100034042 Alcohol dehydrogenase 1C Human genes 0.000 description 2
241000228212 Aspergillus Species 0.000 description 2
101000796894 Coturnix japonica Alcohol dehydrogenase 1 Proteins 0.000 description 2
ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 2
108010088842 Fibrinolysin Proteins 0.000 description 2
108700028146 Genetic Enhancer Elements Proteins 0.000 description 2
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
101000780463 Homo sapiens Alcohol dehydrogenase 1C Proteins 0.000 description 2
101000801742 Homo sapiens Triosephosphate isomerase Proteins 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
206010022998 Irritability Diseases 0.000 description 2
108010067372 Pancreatic elastase Proteins 0.000 description 2
102000016387 Pancreatic elastase Human genes 0.000 description 2
206010033645 Pancreatitis Diseases 0.000 description 2
206010033647 Pancreatitis acute Diseases 0.000 description 2
102000012479 Serine Proteases Human genes 0.000 description 2
108010022999 Serine Proteases Proteins 0.000 description 2
108010022394 Threonine synthase Proteins 0.000 description 2
102100033598 Triosephosphate isomerase Human genes 0.000 description 2
108090000631 Trypsin Proteins 0.000 description 2
102000004142 Trypsin Human genes 0.000 description 2
239000002253 acid Substances 0.000 description 2
201000003229 acute pancreatitis Diseases 0.000 description 2
238000007792 addition Methods 0.000 description 2
239000008272 agar Substances 0.000 description 2
-1 ammonium sulfate Chemical class 0.000 description 2
230000036772 blood pressure Effects 0.000 description 2
229940041514 candida albicans extract Drugs 0.000 description 2
210000000038 chest Anatomy 0.000 description 2
239000002299 complementary DNA Substances 0.000 description 2
230000002596 correlated effect Effects 0.000 description 2
238000006731 degradation reaction Methods 0.000 description 2
102000004419 dihydrofolate reductase Human genes 0.000 description 2
238000009826 distribution Methods 0.000 description 2
239000006167 equilibration buffer Substances 0.000 description 2
230000001434 glomerular Effects 0.000 description 2
239000003102 growth factor Substances 0.000 description 2
230000004060 metabolic process Effects 0.000 description 2
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
210000000496 pancreas Anatomy 0.000 description 2
239000008188 pellet Substances 0.000 description 2
210000000680 phagosome Anatomy 0.000 description 2
239000002504 physiological saline solution Substances 0.000 description 2
229940012957 plasmin Drugs 0.000 description 2
239000011148 porous material Substances 0.000 description 2
210000000512 proximal kidney tubule Anatomy 0.000 description 2
230000009467 reduction Effects 0.000 description 2
230000035939 shock Effects 0.000 description 2
239000001509 sodium citrate Substances 0.000 description 2
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
231100000440 toxicity profile Toxicity 0.000 description 2
230000002103 transcriptional effect Effects 0.000 description 2
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
239000012588 trypsin Substances 0.000 description 2
239000002753 trypsin inhibitor Substances 0.000 description 2
210000005253 yeast cell Anatomy 0.000 description 2
239000012138 yeast extract Substances 0.000 description 2
ZNKZJCICBFSACN-UHFFFAOYSA-N 2-[(2-amino-3-methylbutanoyl)amino]-n-[5-(diaminomethylideneamino)-1-(4-nitroanilino)-1-oxopentan-2-yl]-4-methylpentanamide Chemical compound CC(C)C(N)C(=O)NC(CC(C)C)C(=O)NC(CCCN=C(N)N)C(=O)NC1=CC=C([N+]([O-])=O)C=C1 ZNKZJCICBFSACN-UHFFFAOYSA-N 0.000 description 1
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
LKDMKWNDBAVNQZ-UHFFFAOYSA-N 4-[[1-[[1-[2-[[1-(4-nitroanilino)-1-oxo-3-phenylpropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-oxobutanoic acid Chemical compound OC(=O)CCC(=O)NC(C)C(=O)NC(C)C(=O)N1CCCC1C(=O)NC(C(=O)NC=1C=CC(=CC=1)[N+]([O-])=O)CC1=CC=CC=C1 LKDMKWNDBAVNQZ-UHFFFAOYSA-N 0.000 description 1
206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
PCIFXPRIFWKWLK-YUMQZZPRSA-N Ala-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@H](C)N PCIFXPRIFWKWLK-YUMQZZPRSA-N 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
108010021809 Alcohol dehydrogenase Proteins 0.000 description 1
101710081722 Antitrypsin Proteins 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
WXASLRQUSYWVNE-FXQIFTODSA-N Asp-Cys-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CC(=O)O)N WXASLRQUSYWVNE-FXQIFTODSA-N 0.000 description 1
WZUZGDANRQPCDD-SRVKXCTJSA-N Asp-Phe-Cys Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC(=O)O)N WZUZGDANRQPCDD-SRVKXCTJSA-N 0.000 description 1
241000228245 Aspergillus niger Species 0.000 description 1
240000006439 Aspergillus oryzae Species 0.000 description 1
235000002247 Aspergillus oryzae Nutrition 0.000 description 1
108010023063 Bacto-peptone Proteins 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
101000984722 Bos taurus Pancreatic trypsin inhibitor Proteins 0.000 description 1
101100280051 Brucella abortus biovar 1 (strain 9-941) eryH gene Proteins 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
108090000617 Cathepsin G Proteins 0.000 description 1
102000004173 Cathepsin G Human genes 0.000 description 1
108090000317 Chymotrypsin Proteins 0.000 description 1
108060005980 Collagenase Proteins 0.000 description 1
102000029816 Collagenase Human genes 0.000 description 1
OZHXXYOHPLLLMI-CIUDSAMLSA-N Cys-Lys-Ala Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O OZHXXYOHPLLLMI-CIUDSAMLSA-N 0.000 description 1
102000012410 DNA Ligases Human genes 0.000 description 1
108010061982 DNA Ligases Proteins 0.000 description 1
NOQGZXFMHARMLW-UHFFFAOYSA-N Daminozide Chemical compound CN(C)NC(=O)CCC(O)=O NOQGZXFMHARMLW-UHFFFAOYSA-N 0.000 description 1
UQBOJOOOTLPNST-UHFFFAOYSA-N Dehydroalanine Chemical compound NC(=C)C(O)=O UQBOJOOOTLPNST-UHFFFAOYSA-N 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
241000233866 Fungi Species 0.000 description 1
101150111020 GLUL gene Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
101000679359 Homo sapiens Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase TPTE2 Proteins 0.000 description 1
102000002265 Human Growth Hormone Human genes 0.000 description 1
108010000521 Human Growth Hormone Proteins 0.000 description 1
239000000854 Human Growth Hormone Substances 0.000 description 1
241001135569 Human adenovirus 5 Species 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
229940127379 Kallikrein Inhibitors Drugs 0.000 description 1
SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 1
LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
241000235087 Lachancea kluyveri Species 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
OGUUKPXUTHOIAV-SDDRHHMPSA-N Leu-Glu-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N1CCC[C@@H]1C(=O)O)N OGUUKPXUTHOIAV-SDDRHHMPSA-N 0.000 description 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
108090000157 Metallothionein Proteins 0.000 description 1
101100235161 Mycolicibacterium smegmatis (strain ATCC 700084 / mc(2)155) lerI gene Proteins 0.000 description 1
108010079364 N-glycylalanine Proteins 0.000 description 1
238000011887 Necropsy Methods 0.000 description 1
229930193140 Neomycin Natural products 0.000 description 1
241000221960 Neurospora Species 0.000 description 1
108020005187 Oligonucleotide Probes Proteins 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
239000001888 Peptone Substances 0.000 description 1
108010080698 Peptones Proteins 0.000 description 1
102100022577 Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase TPTE2 Human genes 0.000 description 1
241000276498 Pollachius virens Species 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 description 1
101000605527 Rattus norvegicus Kallikrein-1 Proteins 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
241000582914 Saccharomyces uvarum Species 0.000 description 1
SRTCFKGBYBZRHA-ACZMJKKPSA-N Ser-Ala-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(O)=O SRTCFKGBYBZRHA-ACZMJKKPSA-N 0.000 description 1
LYGKYFKSZTUXGZ-ZDLURKLDSA-N Thr-Cys-Gly Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)NCC(O)=O LYGKYFKSZTUXGZ-ZDLURKLDSA-N 0.000 description 1
MSIYNSBKKVMGFO-BHNWBGBOSA-N Thr-Gly-Pro Chemical compound C[C@H]([C@@H](C(=O)NCC(=O)N1CCC[C@@H]1C(=O)O)N)O MSIYNSBKKVMGFO-BHNWBGBOSA-N 0.000 description 1
NWECYMJLJGCBOD-UNQGMJICSA-N Thr-Phe-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(O)=O NWECYMJLJGCBOD-UNQGMJICSA-N 0.000 description 1
102000057032 Tissue Kallikreins Human genes 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
229940122618 Trypsin inhibitor Drugs 0.000 description 1
101710162629 Trypsin inhibitor Proteins 0.000 description 1
HIINQLBHPIQYHN-JTQLQIEISA-N Tyr-Gly-Gly Chemical compound OC(=O)CNC(=O)CNC(=O)[C@@H](N)CC1=CC=C(O)C=C1 HIINQLBHPIQYHN-JTQLQIEISA-N 0.000 description 1
PHKQVWWHRYUCJL-HJOGWXRNSA-N Tyr-Phe-Tyr Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O PHKQVWWHRYUCJL-HJOGWXRNSA-N 0.000 description 1
108091034131 VA RNA Proteins 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
LPQOADBMXVRBNX-UHFFFAOYSA-N ac1ldcw0 Chemical compound Cl.C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN3CCSC1=C32 LPQOADBMXVRBNX-UHFFFAOYSA-N 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
230000002411 adverse Effects 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
239000011543 agarose gel Substances 0.000 description 1
108010008685 alanyl-glutamyl-aspartic acid Proteins 0.000 description 1
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
229910052921 ammonium sulfate Inorganic materials 0.000 description 1
235000011130 ammonium sulphate Nutrition 0.000 description 1
208000003455 anaphylaxis Diseases 0.000 description 1
230000001475 anti-trypsic effect Effects 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
239000002585 base Substances 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
235000011148 calcium chloride Nutrition 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
238000005341 cation exchange Methods 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
230000002759 chromosomal effect Effects 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
229960002376 chymotrypsin Drugs 0.000 description 1
230000005796 circulatory shock Effects 0.000 description 1
229960002424 collagenase Drugs 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
239000005289 controlled pore glass Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
238000001816 cooling Methods 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000000254 damaging effect Effects 0.000 description 1
230000034994 death Effects 0.000 description 1
231100000517 death Toxicity 0.000 description 1
230000007423 decrease Effects 0.000 description 1
230000007547 defect Effects 0.000 description 1
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
210000003527 eukaryotic cell Anatomy 0.000 description 1
210000003722 extracellular fluid Anatomy 0.000 description 1
239000003527 fibrinolytic agent Substances 0.000 description 1
230000003480 fibrinolytic effect Effects 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
235000019253 formic acid Nutrition 0.000 description 1
229930182830 galactose Natural products 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
210000004907 gland Anatomy 0.000 description 1
230000024924 glomerular filtration Effects 0.000 description 1
239000008103 glucose Substances 0.000 description 1
230000002414 glycolytic effect Effects 0.000 description 1
VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
229960001340 histamine Drugs 0.000 description 1
238000002744 homologous recombination Methods 0.000 description 1
230000006801 homologous recombination Effects 0.000 description 1
230000000988 hyperfibrinolytic effect Effects 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
230000010354 integration Effects 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
230000003902 lesion Effects 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
238000009630 liquid culture Methods 0.000 description 1
210000005228 liver tissue Anatomy 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
210000002751 lymph Anatomy 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
239000003550 marker Substances 0.000 description 1
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
229960000485 methotrexate Drugs 0.000 description 1
244000005700 microbiome Species 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
230000003589 nefrotoxic effect Effects 0.000 description 1
229960004927 neomycin Drugs 0.000 description 1
231100001210 nonnephrotoxic Toxicity 0.000 description 1
239000002751 oligonucleotide probe Substances 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
239000000082 organ preservation Substances 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
210000003681 parotid gland Anatomy 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
229960001412 pentobarbital Drugs 0.000 description 1
WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
235000019319 peptone Nutrition 0.000 description 1
230000035699 permeability Effects 0.000 description 1
JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 1
150000008300 phosphoramidites Chemical class 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
239000011505 plaster Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
239000004033 plastic Substances 0.000 description 1
230000008488 polyadenylation Effects 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229940057838 polyethylene glycol 4000 Drugs 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
230000001376 precipitating effect Effects 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
239000000047 product Substances 0.000 description 1
108010077112 prolyl-proline Proteins 0.000 description 1
235000019833 protease Nutrition 0.000 description 1
210000001938 protoplast Anatomy 0.000 description 1
238000000746 purification Methods 0.000 description 1
230000003362 replicative effect Effects 0.000 description 1
238000004007 reversed phase HPLC Methods 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
239000000523 sample Substances 0.000 description 1
239000007261 sc medium Substances 0.000 description 1
238000012216 screening Methods 0.000 description 1
239000013605 shuttle vector Substances 0.000 description 1
108010070880 sigma K Proteins 0.000 description 1
238000002741 site-directed mutagenesis Methods 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
210000001082 somatic cell Anatomy 0.000 description 1
210000000952 spleen Anatomy 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
238000010972 statistical evaluation Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
206010043554 thrombocytopenia Diseases 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
229940108519 trasylol Drugs 0.000 description 1
229960001322 trypsin Drugs 0.000 description 1
108010017949 tyrosyl-glycyl-glycine Proteins 0.000 description 1
241000701161 unidentified adenovirus Species 0.000 description 1
210000003932 urinary bladder Anatomy 0.000 description 1
230000002485 urinary effect Effects 0.000 description 1
230000036325 urinary excretion Effects 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
238000005406 washing Methods 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
238000005303 weighing Methods 0.000 description 1
230000029663 wound healing Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8114—Kunitz type inhibitors
- C07K14/8117—Bovine/basic pancreatic trypsin inhibitor (BPTI, aprotinin)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Biophysics (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Life Sciences & Earth Sciences (AREA)
Gastroenterology & Hepatology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)

NO931220A 1990-10-01 1993-03-31 Aprotininanaloger NO309529B1 (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
DK236190A DK236190D0 (da)	1990-10-01	1990-10-01	Polypeptid
DK111891A DK111891D0 (da)	1991-06-12	1991-06-12	Polypeptid
PCT/DK1991/000299 WO1992006111A1 (en)	1990-10-01	1991-10-01	Aprotinin analogues

Publications (3)

Publication Number	Publication Date
NO931220D0 NO931220D0 (no)	1993-03-31
NO931220L NO931220L (no)	1993-04-01
NO309529B1 true NO309529B1 (no)	2001-02-12

Family

ID=26065261

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO931220A NO309529B1 (no)	1990-10-01	1993-03-31	Aprotininanaloger

Country Status (21)

Country	Link
EP (1)	EP0551329B1 (de)
JP (1)	JP3614850B2 (de)
KR (1)	KR100250391B1 (de)
AT (1)	ATE168414T1 (de)
AU (1)	AU659100B2 (de)
CA (1)	CA2092920A1 (de)
CZ (1)	CZ285225B6 (de)
DE (1)	DE69129809T2 (de)
DK (1)	DK0551329T3 (de)
ES (1)	ES2121787T3 (de)
FI (1)	FI105036B (de)
HU (1)	HU219302B (de)
IE (1)	IE913433A1 (de)
IL (1)	IL99585A0 (de)
MX (1)	MX9101382A (de)
NO (1)	NO309529B1 (de)
NZ (1)	NZ240014A (de)
PT (1)	PT99124B (de)
SK (1)	SK281540B6 (de)
UA (1)	UA34422C2 (de)
WO (1)	WO1992006111A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6057287A (en)	1994-01-11	2000-05-02	Dyax Corp.	Kallikrein-binding "Kunitz domain" proteins and analogues thereof
AU738766B2 (en) *	1994-11-21	2001-09-27	University Of Leeds, The	Modified proteinase inhibitors
RU2182598C2 (ru) *	1994-11-21	2002-05-20	Новартис Аг	Модифицированные ингибиторы протеиназы
DE19629982A1 (de) *	1996-07-25	1998-01-29	Bayer Ag	Aprotinin-Varianten mit verbesserten Eigenschaften
DE19725014A1 (de) *	1997-06-13	1998-12-17	Bayer Ag	Aprotininvarianten mit verbesserten Eigenschaften und Bikunine von Aprotininvarianten
CA2402310A1 (en)	2000-03-08	2001-09-13	Complexe Hospitalier De La Sagamie	Very low density lipoprotein receptor polymorphisms and uses therefor
DK2311432T3 (en)	2002-06-07	2015-02-02	Dyax Corp	Modified Kunitz domain polypeptides and their use in reducing ischemia or the onset of a systemic inflammatory response associated with a surgical procedure
US7153829B2 (en)	2002-06-07	2006-12-26	Dyax Corp.	Kallikrein-inhibitor therapies
TR201900937T4 (tr)	2002-08-28	2019-02-21	Dyax Corp	Organların ve dokuların muhafaza edilmesine yönelik yöntem.
US7235530B2 (en)	2004-09-27	2007-06-26	Dyax Corporation	Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
WO2008077478A1 (en) *	2006-12-22	2008-07-03	Bayer Schering Pharma Aktiengesellschaft	Preparation and use of variants of the kunitz domain 2 of the human placental bikunin gene
DE102007056231A1 (de)	2007-09-08	2009-03-12	Bayer Healthcare Ag	Herstellung und Verwendung von Varianten humander Kunitz-Typ Protease-Inhibitoren (hKTPI)
US8637454B2 (en)	2009-01-06	2014-01-28	Dyax Corp.	Treatment of mucositis with kallikrein inhibitors
ES2688093T3 (es)	2010-01-06	2018-10-30	Dyax Corp.	Proteínas de unión a calicreína plasmática
IL269565B2 (en)	2011-01-06	2024-06-01	Dyax Corp	Plasma kallikrein binding proteins
BR112018011622A2 (pt)	2015-12-11	2018-11-27	Dyax Corp	método para tratar ataque de angioedema hereditário (hae) ou reduzir a taxa de ataque de hae
CA3167336A1 (en)	2020-01-13	2021-07-22	Takeda Pharmaceutical Company Limited	Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB2188322A (en) *	1986-03-26	1987-09-30	Bayer Ag	Aprotinin and analogues thereof produced by a recombinant host
DE3724570A1 (de) *	1987-06-27	1989-01-05	Bayer Ag	Human-aprotinin, dessen lys-rest in position 15 gegen einen anderen protogenen aminosaeurerest ausgetauscht ist
DK225488D0 (da) *	1988-04-26	1988-04-26	Novo Industri As	Polypeptid
DK450187D0 (da) *	1987-08-28	1987-08-28	Novo Industri As	Fremgangsmaade til fremstilling af proteiner
DE3930522A1 (de) *	1989-09-13	1991-03-21	Bayer Ag	Rekombinante aprotinin-varianten - gentechnisches verfahren zur mikrobiellen herstellung von homogen prozessierten aprotinin-varianten sowie die therapeutische anwendung derselben

1991
- 1991-09-27 IL IL99585A patent/IL99585A0/xx unknown
- 1991-09-30 IE IE343391A patent/IE913433A1/en not_active Application Discontinuation
- 1991-09-30 PT PT99124A patent/PT99124B/pt not_active IP Right Cessation
- 1991-09-30 NZ NZ240014A patent/NZ240014A/en unknown
- 1991-10-01 HU HU9300943A patent/HU219302B/hu not_active IP Right Cessation
- 1991-10-01 DK DK91917143T patent/DK0551329T3/da active
- 1991-10-01 MX MX9101382A patent/MX9101382A/es not_active IP Right Cessation
- 1991-10-01 WO PCT/DK1991/000299 patent/WO1992006111A1/en not_active Ceased
- 1991-10-01 CZ CZ93517A patent/CZ285225B6/cs not_active IP Right Cessation
- 1991-10-01 EP EP91917143A patent/EP0551329B1/de not_active Expired - Lifetime
- 1991-10-01 AU AU85460/91A patent/AU659100B2/en not_active Ceased
- 1991-10-01 CA CA002092920A patent/CA2092920A1/en not_active Abandoned
- 1991-10-01 SK SK264-93A patent/SK281540B6/sk unknown
- 1991-10-01 ES ES91917143T patent/ES2121787T3/es not_active Expired - Lifetime
- 1991-10-01 AT AT91917143T patent/ATE168414T1/de not_active IP Right Cessation
- 1991-10-01 JP JP51609991A patent/JP3614850B2/ja not_active Expired - Fee Related
- 1991-10-01 DE DE69129809T patent/DE69129809T2/de not_active Expired - Fee Related
- 1991-10-01 UA UA93002097A patent/UA34422C2/uk unknown
1993
- 1993-03-31 NO NO931220A patent/NO309529B1/no not_active IP Right Cessation
- 1993-03-31 FI FI931457A patent/FI105036B/fi active
- 1993-03-31 KR KR1019930701001A patent/KR100250391B1/ko not_active Expired - Fee Related

Also Published As

Publication number	Publication date
AU8546091A (en)	1992-04-28
WO1992006111A1 (en)	1992-04-16
JP3614850B2 (ja)	2005-01-26
IL99585A0 (en)	1992-08-18
JPH06501158A (ja)	1994-02-10
NZ240014A (en)	1992-08-26
EP0551329A1 (de)	1993-07-21
DE69129809D1 (de)	1998-08-20
FI931457A0 (fi)	1993-03-31
DE69129809T2 (de)	1998-11-19
EP0551329B1 (de)	1998-07-15
SK281540B6 (sk)	2001-04-09
ES2121787T3 (es)	1998-12-16
CA2092920A1 (en)	1992-04-02
FI931457L (fi)	1993-03-31
CZ51793A3 (en)	1994-01-19
PT99124B (pt)	1999-03-31
MX9101382A (es)	1992-06-05
CZ285225B6 (cs)	1999-06-16
HU9300943D0 (en)	1993-06-28
NO931220L (no)	1993-04-01
HU219302B (en)	2001-03-28
NO931220D0 (no)	1993-03-31
SK26493A3 (en)	1993-10-06
IE913433A1 (en)	1992-04-08
DK0551329T3 (da)	1999-04-19
AU659100B2 (en)	1995-05-11
FI105036B (fi)	2000-05-31
UA34422C2 (uk)	2001-03-15
ATE168414T1 (de)	1998-08-15
PT99124A (pt)	1992-08-31
HUT69955A (en)	1995-09-28
KR100250391B1 (ko)	2000-05-01

Legal Events

Date	Code	Title	Description
2003-06-02	MM1K	Lapsed by not paying the annual fees	Free format text: LAPSED IN APRIL 2003

Publication	Publication Date	Title
EP0339942B1 (de)	1994-03-23	Aprotinin-Analoge und Verfahren zu ihrer Herstellung
KR100278036B1 (ko)	2001-01-15	사람 쿠니즈형 프로테아제 저해제 변이체
AU675926B2 (en)	1997-02-27	A human kunitz-type protease inhibitor variant
EP0621869B1 (de)	1997-04-23	Inhibitorvarianten der menschlichen protease vom kunitz-typ
AU675925B2 (en)	1997-02-27	A human kunitz-type protease inhibitor variant
EP0551329B1 (de)	1998-07-15	Aprotininanaloga
US5618696A (en)	1997-04-08	Human kunitz-type protease inhibitor and variants thereof
WO1997033996A9 (en)	1998-05-22	Human bikunin
JP2001521367A (ja)	2001-11-06	ヒトビクニン
US5618915A (en)	1997-04-08	Aprotinin analogs
PL168250B1 (pl)	1996-01-31	Spasób wydarzania analogu aprotyniny